Description

Carfilzomib is a potent, selective, and irreversible proteasome inhibitor, a critical active pharmaceutical ingredient (API) in oncology therapeutics. Its primary value lies in its targeted mechanism of action, which disrupts protein degradation in cancer cells, leading to apoptosis. This compound is essential for pharmaceutical manufacturers and research institutions developing treatments for relapsed or refractory multiple myeloma. Carfilzomib CAS NO 868540-17-4 represents a high-purity component for advanced therapeutic formulations and clinical research.

Application

• Pharmaceutical API: Primary use as the active ingredient in injectable formulations for the treatment of multiple myeloma.
• Oncology Research: A key tool compound for in vitro and in vivo studies investigating proteasome inhibition, cancer cell biology, and mechanisms of drug resistance.
• Drug Development: Serves as a reference standard and a building block in the synthesis of novel proteasome inhibitors or conjugate drugs.
• Clinical Trial Material (CTM): Supplied under GMP conditions for use in Phase I-III clinical trials.
• Bioscience Studies: Used in biochemical assays to study protein homeostasis, ubiquitin-proteasome pathway dynamics, and cellular stress responses.

Basic Information

Product Name	Carfilzomib
CAS No.	868540-17-4
Molecular Formula	C40H57N5O7
Molecular Weight	719.91 g/mol
Synonyms	Kyprolis (trade name); PR-171; (S)-N-((S)-1-((S)-4-Methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide; Carfilzomibum; UNII-72X6E3J5AR
EINECS	Contact for details

Quality Control

Our Carfilzomib is manufactured and tested to meet stringent pharmaceutical-grade standards. Quality assurance protocols align with current Good Manufacturing Practices (cGMP) and ICH guidelines. Each batch is supported by a comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles. Specifications are designed to comply with pharmacopeial requirements for advanced oncology APIs, ensuring reliability and consistency for critical applications.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) or as specified on the label. This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage under inert atmosphere, please contact us for specific recommendations.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Individual impurity ≤0.5%; Total impurities ≤2.0%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤1.0%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.